News stories about "Nordisk" in India.

Novo Nordisk and Valo to research cardiometabolic treatments

Danish drugmaker Novo Nordisk (NOVOb.CO) said on Monday it would collaborate with U.S. tech firm Valo Health to discover and develop new treatments for cardiometabolic diseases using human data and artificial intelligence. Key Points

Reuters

Wegovy maker Novo Nordisk sues Florida pharmacies over copycat drugs

Novo Nordisk (NOVOb.CO) on Thursday accused three Florida pharmacies of illegally selling products claiming to contain semaglutide, the active ingredient in the Danish drugmaker's weight loss and diabetes drugs Wegovy, Ozempic and Rybelsus. Key Points

Reuters

A Chartres, Macron salue un investissement de €2,1 mds de Novo Nordisk

Emmanuel Macron s'est rendu ce jeudi à Chartres à l'occasion de l'annonce par le groupe pharmaceutique danois Novo Nordisk (NOVOb.CO) d'un investissement de 2,1 milliards d'euros pour développer et diversifier son site en Eure-et-Loir, alors que le président de la République s'efforce de se présenter en champion de la réindustrialisation de la France. Key Points

Reuters

Global health heavyweights team up for climate change, infectious diseases funding

Novo Nordisk Foundation, Wellcome and the Bill & Melinda Gates Foundation to put $100 million each. Three of the biggest global health funders have joined forces... Key Points

The Tribune India

Novo Nordisk, maker of Ozempic and Wegovy sues two pharmacies for ‘selling impure drugs’

Over alleged selling of contaminated drugs, two Florida-based pharmacies have been sued by Novo Nordisk. The company claims that the substance used for the production of the drugs does not have approval from the FDA. Key Points

Economic Times

Tema ETFs hops on weight-loss drug frenzy with its new cardiovascular fund

Tema ETFs has launched a new exchange traded fund (ETF) that tracks popular drugmakers like Novo Nordisk (NOVOb.CO) and Eli Lilly (LLY.N), aiming to tap into growing demand for their weight-loss and diabetes drugs. Key Points

Reuters

Novo Nordisk va investir $6 mds pour stimuler la production de Wegovy - DG

Novo Nordisk (NOVOb.CO), le fabricant du médicament Wegovy pour la perte de poids, a annoncé vendredi qu'il investirait 6 milliards de dollars (5,62 milliards d'euros) pour stimuler sa production au Danemark, tout en signalant que l'industrie était loin d'être en mesure de produire suffisamment de traitements amaigrissants pour répondre à la demande mondiale. Key Points

Reuters

US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic

A U.S. Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo Nordisk (NOVOb.CO) covering the active ingredient in its weight-loss and diabetes drugs Wegovy and Ozempic brought by a generic drugmaker that is hoping to sell generic versions of the blockbuster medications. Key Points

Reuters

Investors increase holdings of weight-loss drug makers’ shares in Q3 -filings

Some big investors showed increased appetite for weight-loss drug makers in the third quarter, piling in to shares of Eli Lilly (LLY.N) and Novo Nordisk amid growing demand for their product, securities filings showed on Tuesday. Key Points

Reuters

Weight-loss drug maker Novo Nordisk to invest $6 bln in expanding plant

Novo Nordisk (NOVOb.CO) said on Friday it plans to invest more than 42 billion crowns ($6 billion) in the coming years as it seeks to meet booming demand for its Wegovy weight-loss treatment and other drugs. Key Points

Reuters

Novo Nordisk posts record quarterly results, keeps curbs on Wegovy supplies

Novo Nordisk (NOVOb.CO) on Thursday reported record sales and operating profits for the third quarter but said it would keep in place restrictions on supplies of its hugely popular Wegovy weight-loss drug. Key Points

Reuters

Novo Nordisk owner sees chance to go public will open within 18 months

The CEO of Novo Holdings, the controlling shareholder in drugmaker Novo Nordisk (NOVOb.CO), said on Tuesday he sees the window for initial public offerings (IPOs) opening within 18 months and is encouraging portfolio companies to get ready. Key Points

Reuters

Weight loss ‘wonder drug’ semaglutide can cut down risk of heart disease, says Danish drugmaker

Novo Nordisk says results of its trials show a 2.4 mg dose can cut down major heart-related ailments by 20%, and the study will be published in a peer-reviewed journal by end of year. Key Points

ThePrint